Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma

Theodore Wun, Hayes McKnight, Joseph Tuscano

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

B cell lymphomas are a diverse group of clinicopathologic diseases with an increasing incidence. As with other malignancies, the accumulation of genetic abnormalities are required for malignant transformation of human lymphocytes. Cyclooxygenase-2 (COX-2) is a key biosynthetic enzyme in prostaglandin synthesis and has been implicated in the pathogenesis of numerous malignancies including colon, breast, and lung cancer. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In this study, several B lymphoma cell lines and primary B cells obtained from normal volunteer controls were examined for COX-2 protein expression. Immunoblot analysis demonstrated between an approximately 2.2-4.3-fold increase in COX-2 protein expression relative to primary B cells in all lymphoma cell lines examined. Increased COX-2 phosphorylation was found in the BJAB, BL41, and Raji cells whereas the levels in Daudi, Namalwa, and Ramos did not differ from that of primary B cells. Treatment with 25-100μM celecoxib (CEL) resulted in decreased proliferation as measured by [3H]thymidine in all cell lines examined, and the effect was dose-dependent, and not significantly enhanced by chlorambucil (CHL). The effect of COX-2 inhibition on apoptosis in lymphoma cells was examined and revealed apoptotic induction of greater than 85% in all cell lines examined at 50μM celecoxib. The pro-apoptotic effect was dose-dependent, and was not significantly enhanced by chlorambucil. Examination of apoptosis-related proteins by immunoblot analysis revealed levels of BCL-2, BCL-XL, and Bax to be unaffected by celecoxib. In contrast, levels of Akt, MCL-1, and phosphorylated SAP-kinase were all decreased after incubation with 50μM celecoxib. These findings suggest that increased COX-2 expression and activity, contributes to the pathogenesis of B cell lymphomas and point to a possible role for COX-2 inhibition in their treatment.

Original languageEnglish (US)
Pages (from-to)179-190
Number of pages12
JournalLeukemia Research
Volume28
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Celecoxib
Cyclooxygenase 2
Lymphoma
Chlorambucil
Cell Line
B-Lymphocytes
B-Cell Lymphoma
Mitogen-Activated Protein Kinase 8
Apoptosis
Proteins
Lymphocyte Activation
Colonic Neoplasms
Thymidine
Prostaglandins
Lung Neoplasms
Neoplasms
Healthy Volunteers
Phosphorylation
Breast Neoplasms
Incidence

Keywords

  • Cyclooxygenase-2
  • Lymphoma
  • Pro-apoptotic effect

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Increased cyclooxygenase-2 (COX-2) : A potential role in the pathogenesis of lymphoma. / Wun, Theodore; McKnight, Hayes; Tuscano, Joseph.

In: Leukemia Research, Vol. 28, No. 2, 02.2004, p. 179-190.

Research output: Contribution to journalArticle

@article{32ffff07b7e247388cf0838d0660ea04,
title = "Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma",
abstract = "B cell lymphomas are a diverse group of clinicopathologic diseases with an increasing incidence. As with other malignancies, the accumulation of genetic abnormalities are required for malignant transformation of human lymphocytes. Cyclooxygenase-2 (COX-2) is a key biosynthetic enzyme in prostaglandin synthesis and has been implicated in the pathogenesis of numerous malignancies including colon, breast, and lung cancer. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In this study, several B lymphoma cell lines and primary B cells obtained from normal volunteer controls were examined for COX-2 protein expression. Immunoblot analysis demonstrated between an approximately 2.2-4.3-fold increase in COX-2 protein expression relative to primary B cells in all lymphoma cell lines examined. Increased COX-2 phosphorylation was found in the BJAB, BL41, and Raji cells whereas the levels in Daudi, Namalwa, and Ramos did not differ from that of primary B cells. Treatment with 25-100μM celecoxib (CEL) resulted in decreased proliferation as measured by [3H]thymidine in all cell lines examined, and the effect was dose-dependent, and not significantly enhanced by chlorambucil (CHL). The effect of COX-2 inhibition on apoptosis in lymphoma cells was examined and revealed apoptotic induction of greater than 85{\%} in all cell lines examined at 50μM celecoxib. The pro-apoptotic effect was dose-dependent, and was not significantly enhanced by chlorambucil. Examination of apoptosis-related proteins by immunoblot analysis revealed levels of BCL-2, BCL-XL, and Bax to be unaffected by celecoxib. In contrast, levels of Akt, MCL-1, and phosphorylated SAP-kinase were all decreased after incubation with 50μM celecoxib. These findings suggest that increased COX-2 expression and activity, contributes to the pathogenesis of B cell lymphomas and point to a possible role for COX-2 inhibition in their treatment.",
keywords = "Cyclooxygenase-2, Lymphoma, Pro-apoptotic effect",
author = "Theodore Wun and Hayes McKnight and Joseph Tuscano",
year = "2004",
month = "2",
doi = "10.1016/S0145-2126(03)00183-8",
language = "English (US)",
volume = "28",
pages = "179--190",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Increased cyclooxygenase-2 (COX-2)

T2 - A potential role in the pathogenesis of lymphoma

AU - Wun, Theodore

AU - McKnight, Hayes

AU - Tuscano, Joseph

PY - 2004/2

Y1 - 2004/2

N2 - B cell lymphomas are a diverse group of clinicopathologic diseases with an increasing incidence. As with other malignancies, the accumulation of genetic abnormalities are required for malignant transformation of human lymphocytes. Cyclooxygenase-2 (COX-2) is a key biosynthetic enzyme in prostaglandin synthesis and has been implicated in the pathogenesis of numerous malignancies including colon, breast, and lung cancer. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In this study, several B lymphoma cell lines and primary B cells obtained from normal volunteer controls were examined for COX-2 protein expression. Immunoblot analysis demonstrated between an approximately 2.2-4.3-fold increase in COX-2 protein expression relative to primary B cells in all lymphoma cell lines examined. Increased COX-2 phosphorylation was found in the BJAB, BL41, and Raji cells whereas the levels in Daudi, Namalwa, and Ramos did not differ from that of primary B cells. Treatment with 25-100μM celecoxib (CEL) resulted in decreased proliferation as measured by [3H]thymidine in all cell lines examined, and the effect was dose-dependent, and not significantly enhanced by chlorambucil (CHL). The effect of COX-2 inhibition on apoptosis in lymphoma cells was examined and revealed apoptotic induction of greater than 85% in all cell lines examined at 50μM celecoxib. The pro-apoptotic effect was dose-dependent, and was not significantly enhanced by chlorambucil. Examination of apoptosis-related proteins by immunoblot analysis revealed levels of BCL-2, BCL-XL, and Bax to be unaffected by celecoxib. In contrast, levels of Akt, MCL-1, and phosphorylated SAP-kinase were all decreased after incubation with 50μM celecoxib. These findings suggest that increased COX-2 expression and activity, contributes to the pathogenesis of B cell lymphomas and point to a possible role for COX-2 inhibition in their treatment.

AB - B cell lymphomas are a diverse group of clinicopathologic diseases with an increasing incidence. As with other malignancies, the accumulation of genetic abnormalities are required for malignant transformation of human lymphocytes. Cyclooxygenase-2 (COX-2) is a key biosynthetic enzyme in prostaglandin synthesis and has been implicated in the pathogenesis of numerous malignancies including colon, breast, and lung cancer. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In this study, several B lymphoma cell lines and primary B cells obtained from normal volunteer controls were examined for COX-2 protein expression. Immunoblot analysis demonstrated between an approximately 2.2-4.3-fold increase in COX-2 protein expression relative to primary B cells in all lymphoma cell lines examined. Increased COX-2 phosphorylation was found in the BJAB, BL41, and Raji cells whereas the levels in Daudi, Namalwa, and Ramos did not differ from that of primary B cells. Treatment with 25-100μM celecoxib (CEL) resulted in decreased proliferation as measured by [3H]thymidine in all cell lines examined, and the effect was dose-dependent, and not significantly enhanced by chlorambucil (CHL). The effect of COX-2 inhibition on apoptosis in lymphoma cells was examined and revealed apoptotic induction of greater than 85% in all cell lines examined at 50μM celecoxib. The pro-apoptotic effect was dose-dependent, and was not significantly enhanced by chlorambucil. Examination of apoptosis-related proteins by immunoblot analysis revealed levels of BCL-2, BCL-XL, and Bax to be unaffected by celecoxib. In contrast, levels of Akt, MCL-1, and phosphorylated SAP-kinase were all decreased after incubation with 50μM celecoxib. These findings suggest that increased COX-2 expression and activity, contributes to the pathogenesis of B cell lymphomas and point to a possible role for COX-2 inhibition in their treatment.

KW - Cyclooxygenase-2

KW - Lymphoma

KW - Pro-apoptotic effect

UR - http://www.scopus.com/inward/record.url?scp=0344152223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344152223&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00183-8

DO - 10.1016/S0145-2126(03)00183-8

M3 - Article

C2 - 14654083

AN - SCOPUS:0344152223

VL - 28

SP - 179

EP - 190

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -